Outcomes of SARS-CoV-2 Infection among Children and Young People with Pre-existing Rheumatic and Musculoskeletal Diseases.

Authors
Lianne Kearsley-Fleet*1, Min-Lee Chang*2, Saskia Lawson-Tovey3,4, Ruth Costello1, Šárka Fingerhutová5, Natálie Švestková6, Alexandre Belot6, Florence A. Aeschlimann7, Isabelle Melki8,9,10, Isabelle Kone-Paut11, Sascha Eulert12, Tilmann Kallinich13, Yackov Berkun14,15, Yosef Uziel16,17, Bernd Raffeiner18, Filipa Oliveira-Ramos19, Daniel Clemente20, Christina Dackhammar21, Nico M. Wulffraat22,23, Helen Waite24, Anja Strangfeld25, Elsa Mateus26, Pedro M. Machado27,28,29, CARRA Registry Investigators***, COVID-19 Global Pediatric Rheumatology Database Investigators****, Marc Natter**2, Kimme L. Hyrich**1,4.

1Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
2Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, USA.
3Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
4National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
5General University Hospital, Prague, Czechia.
6Pediatric Nephrology, Rheumatology, Dermatology Department, HFME, Hospices Civils de Lyon, Université Lyon-1, Lyon, France.
7Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, Paris, France.
8General Pediatrics, Infectious Disease and Internal Medicine Department, Hôpital Robert Debre, AP-HP, Paris, France, Reference center for Rheumatic, Autoimmune and Systemic diseases in children (RAISE).
9Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris, France, Reference center for Rheumatic, Autoimmune and Systemic diseases in children (RAISE).
10Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris, France.
11Bicêtre Hospital, Paris, France.
12German Rheumatism Research Center (DRFZ Berlin), Epidemiology Unit, Berlin, Germany.
13Charité Universitätsmedizin Berlin, Berlin, Germany.
14Department of Pediatrics, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem, Israel.
15Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
16Paediatric Rheumatology Unit, Department of Paediatrics, Meir Medical Centre, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
17Pediatric Rheumatology European Society (PReS).
18Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy.
19Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
Hospital Niño Jesús, Madrid, Spain.
Sahlgrenska University Hospital, Sweden.
University Medical Center, Utrecht, The Netherlands;
European Reference Network RITA.
Atrius Health Inc., Newton, MA, USA.
Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.
European Alliance of Associations for Rheumatology (EULAR) Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Kilchberg, Switzerland.
Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.
National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.

Competing interests: LKF, MLC, SLT, SF, NS, AB, FAA, IM, SE, TK, YB, YU, BR, DC, CD, and HW report no disclosures. RC reports personal AstraZeneca shares, unrelated to this manuscript. IKP reports personal fees by Novartis, SOBI, Chugai, Pfizer, AbbVie, BMS, all unrelated to this manuscript. FOR reports consulting/speaker’s fees from Abbvie, Novartis, Pfizer and Sobi, all unrelated to this manuscript. NMW reports personal consultant fees from UCB, BMS, all unrelated to this manuscript. AS reports personal fees from lectures for AbbVie, Celltrion, MSD, Janssen, Lilly, Roche, BMS, and Pfizer, all unrelated to this manuscript. EM reports personal consultant fees from Boehringer Ingelheim Portugal, Lda, all unrelated to this manuscript. LPCDR received support for specific activities: grants from Abbvie, Novartis, Lilly Portugal, Amgen Biofarmacêutica, Grünenthal S.A., MSD, Medac, A. Menarini Portugal - Farmacêutica, S.A., Pfizer, UCB Pharma, ROCHE Farmacêutica Química, Lda; and non-financial support from Pfizer, and Grünenthal GmbH, all unrelated to this manuscript. PMM reports consulting/speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript, and is supported by the National Institute for Health Research (NIHR), University College London Hospitals (UCLH), Biomedical Research Centre (BRC). MN reports funding from Childhood Arthritis & Rheumatology Research Alliance, Inc (CARRA) to his informatics research and operations group at Boston Children’s Hospital in its capacity as the CARRA Data Warehouse and associated work for CARRA and the CARRA Registry and has sponsored the COVID-19 Global Pediatric Rheumatology Database study, of which he is the Principal Investigator. MN also serves as Director of Informatics for CARRA, for which he receives no direct compensation but do receive research sponsorship for CARRA-related research, development, and operations (see above). He is also a co-investigator of the CARRA Registry and site Principal Investigator at Massachusetts General Hospital. KLH reports non-personal speaker’s fees from Abbvie and grant income from BMS, UCB, and Pfizer, all unrelated to this manuscript, and is supported by the NIHR Manchester Biomedical Research Centre.

*Lianne Kearsley-Fleet and Min-Lee Chang are joint first authors as they contributed equally to this manuscript.

**Marc Natter and Kimme L. Hyrich are joint senior authors.

***CARRA Registry Investigators author list in Supplementary Materials.
**COVID-19 GPRD Investigators author list in Supplementary Materials.**

**Correspondence to:** Prof. Kimme L. Hyrich

Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, M13 9PL, United Kingdom

Kimme.hyrich@manchester.ac.uk

**Word count manuscript:** 3144

**Tables:** 3

**References:** 20

**Keywords:** COVID-19, JIA, SLE, adverse events, RMDs, hospitalisation, death, observational study, registry.

**Key messages:**

- **What is already known about this subject?**
  - Some adults with rheumatic and musculoskeletal diseases (RMDs) are at increased risk of COVID-19-related death.

- **What does this study add?**
  - Hospitalisation for COVID-19 among children and young people with underlying RMDs were rare in this study with the majority having mild affects only.
  - Treatment with biologics, such as TNF inhibitors, did not appear to be associated with more severe COVID-19 in children and young people with RMDs.

- **How might this impact on clinical practice or future developments?**
  - Whilst protective measures, as indicated by local policy, are important to follow with respect to minimising risk of acquiring SARS-CoV-2 infection, parents and families can be reassured that these data do not support a high probability of severe COVID-19 in the majority of children and young people with underlying RMDs.
Abstract

Objectives: Some adults with rheumatic and musculoskeletal diseases (RMDs) are at increased risk of COVID-19-related death. Excluding post-COVID-19 multisystem inflammatory syndrome of children, children and young people (CYP) are overall less prone to severe COVID-19 and most experience a mild or asymptomatic course. However, it is unknown if CYP with RMDs are more likely to have more severe COVID-19. This analysis aims to describe outcomes among CYP with underlying RMDs with COVID-19.

Methods: Using the European Alliance of Associations for Rheumatology (EULAR) COVID-19 Registry, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, and the CARRA-sponsored COVID-19 Global Paediatric Rheumatology Database (COVID-19 GPRD), we obtained data on CYP with RMDs who reported SARS-CoV-2 infection (presumptive or confirmed). Patient characteristics and illness severity were described, and factors associated with COVID-19 hospitalisation were investigated.

Results: 607 CYP with RMDs <19 years-old from 25 different countries with SARS-CoV-2 infection were included, the majority with juvenile idiopathic arthritis (JIA; N=378; 62%). Forty-three (7%) patients were hospitalised; three of these patients died. Compared with JIA, diagnosis of systemic lupus erythematosus, mixed connective tissue disease, vasculitis, or other RMD (OR 4.3; 95%CI 1.7, 11) or auto-inflammatory syndrome (OR 3.0; 95%CI 1.1, 8.6) was associated with hospitalisation, as was obesity (OR 4.0; 95%CI 1.3, 12).

Conclusions: This is the most significant investigation to date of COVID-19 in CYP with RMDs. It is important to note that the majority of CYP were not hospitalised, although those with severe systemic RMDs and obesity were more likely to be hospitalised.
Background

Worldwide, as of 11th January 2022, there were over 308 million confirmed cases of COVID-19, including over 5.4 million deaths.[1] The collective experience is that children, especially younger children, seem less susceptible to symptomatic Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) illness and reports of death are rare.[2,3] However, less is known about the impact of comorbidity and especially immunosuppression on the risk of severe COVID-19 in the paediatric population.

Data from one analysis of adults with rheumatic and musculoskeletal diseases (RMDs) has shown that presence of rheumatoid arthritis, lupus or psoriasis (as a group) is associated with increased risk of COVID-19-related death compared with those without comorbid RMDs.[4] However, this analysis did not account for the effects of treatments or disease activity. In another analysis of almost 4,000 adults with RMDs, moderate to high RMD disease activity and certain types of therapies (e.g. B-cell depletion, alkylating agents) were associated with COVID-19-related death.[5] A recent systematic literature review suggested that the increased risk of severe COVID-19 cannot be generalised to all patients with RMDs and it is probably restricted to very specific subgroups of patients with RMDs.[6]

According to data from seven countries, as of January/February 2021, approximately 1.7 deaths per 1,000,000 population attributable to COVID-19 have occurred in individuals up to 19 years old, contributing 0.48% of estimated total all-cause mortality.[7] In a recent (pre-print) systematic review of children and young people with COVID-19, those with comorbid conditions were at increased risk of hospital admissions to critical care, although only eight patients in this review were considered to have an RMD.[8]

It remains unknown whether children and young people with RMDs who acquire COVID-19 have a more severe COVID-19 course and if there is additional risk attributable to either underlying disease or its therapy. It is important to understand the impact of COVID-19 on these individuals to inform national guidelines on protective measures (i.e. recommendations to stay home and avoid face-to-face contact), vaccination guidance, and address individual decisions regarding heightened social distancing measures for paediatric RMD patients and their families. Critically for this age group is the need to ensure they continue to have full and appropriate access to school and education, with in-person attendance if safe to do so.

Around the recognised outset of the COVID-19 pandemic, individual national and international efforts to collect, analyse, and disseminate data about COVID-19 in patients with paediatric RMDs were rapidly established. In collaboration with the COVID-19 Global Rheumatology Alliance,[9] there were three organised cooperative efforts for COVID-19 in paediatric RMDs internationally: (1) the European Alliance of Associations for Rheumatology (EULAR)/Paediatric Rheumatology European Society (PReS) sponsored COVID-19 Registry, consisting of >10,000 clinician-entered reports of individuals with RMDs with COVID-19[10] including children, collecting cases from across Europe; (2) inclusion of SARS-CoV-2 infection reporting for the United States Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry; (3) the CARRA-sponsored COVID-19 Global Paediatric Rheumatology Database (COVID-19 GPRD) for international reporting of subjects not covered by either of the other two efforts. Data collection was designed to align between efforts and this collaboration has yielded the largest collection of COVID-19-related data for patients with paediatric onset RMDs to date.
The aims of this global analysis are: (1) to describe characteristics of those children and young people with pre-existing RMDs with COVID-19, (2) to describe outcomes following COVID-19, and (3) to identify characteristics that are associated with more severe COVID-19 outcomes.

Methods

Databases
The data analysed comprise cases reported to the EULAR COVID-19 Registry, the CARRA Registry, and the COVID-19 GPRD. Data were entered by the treating rheumatologist or their designee directly into data entry websites. For some countries in Europe (France, Germany, Greece, Italy, Portugal and Sweden), under an existing agreement, cases were transferred from other national COVID-19 registries into the EULAR COVID-19 Registry. It was not possible for patients or families to report directly into any of the registries, but mild or asymptomatic cases of COVID-19 reported to a rheumatologist could be entered subsequently by a physician. The EULAR COVID-19 Registry data were collected and managed using REDCap (Research Electronic Data Capture) tools hosted at The University of Manchester, United Kingdom.[11] REDCap is a secure, web-based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. The COVID-19 GPRD study is operated by Boston Children’s Hospital (USA) and utilizes REDCap Cloud (nPhase, Inc., USA) for data entry from the USA, Canada, and international sites not participating in the EULAR COVID-19 Registry. For patients with RMDs enrolled in the CARRA Registry (prospective observational cohort) and who also tested positive for SARS-CoV-2 infection, data are collected in Rave (Medidata Solutions Inc., USA). Data reported in the EULAR COVID-19 Registry and the COVID-19 GPRD are collected on an ad hoc basis. CARRA Registry investigators were instructed to report all SARS-CoV-2 infections in registry subjects as a safety event of special interest (ESI). Complete CARRA Registry ESI reports were validated, abstracted, and combined with data from the COVID-19 GPRD; these data elements were then mapped to and harmonized with the EULAR COVID-19 Registry dataset for combined data analyses.

Data Collection
The data collected across the registries include patient demographic information (age, sex at birth, country of residence), primary RMD diagnosis, RMD disease activity (tick box: remission, low, moderate, high, or unknown), RMD treatments including glucocorticoid use and which disease modifying anti-rheumatic drug (DMARD) the patient was on at the time of COVID-19, and comorbidities (tick box: none, ocular inflammation, interstitial lung disease, asthma, diabetes, obesity, hypertension, cerebrovascular accident, renal disease, inflammatory bowel disease, heart disease). Information on COVID-19 include diagnosis date, whether the case was presumptive or confirmed (via PCR, antigen test, antibody test, or other laboratory assay), clinical symptoms (tick box), hospitalisation and/or death due to COVID-19, and whether the patient stopped rheumatic therapies.
ETHICS APPROVAL
The EULAR COVID-19 physician-reported Registry was determined “not human subjects’ research” by the UK Health Research Authority and the University of Manchester and no informed consent was required for anonymous data to be uploaded to the registry. The CARRA Registry is approved by the Duke University IRB (Pro00054616), and informed consent was obtained for participation in the CARRA Registry. COVID-19 GPR Database is approved by the Boston Children’s Hospital IRB (P00034912) on an expedited basis, with waiver of informed consent and authorisation.

INCLUSION CRITERIA
All children and young people <19 years of age at the time of detection of SARS-CoV-2 infection or the development of COVID-19 illness (presumptive or confirmed) were included in the primary analyses. Individuals with juvenile idiopathic arthritis (JIA) aged 19 and over were included for additional descriptive analyses. The CARRA Registry required documentation of positive SARS-CoV-2 testing (PCR, antigen, or antibody) in order to be validated as a COVID-19 ESI. These cases underwent validation by two independent reviewers.

Cases for this analysis were included from initial COVID-19 date (EULAR COVID-19 Registry: 27th March 2020; CARRA Registry: 1st March 2020; COVID-19 GPRD: 13th April 2020) until a cut-off date of 20th July 2021 for the EULAR COVID-19 Registry, 25th May 2021 for the CARRA Registry, and 23rd June 2021 for the COVID-19 GPRD.

STATISTICAL ANALYSIS
Demographic characteristics of all children and young people aged <19 years were described using relevant categorical and continuous variables and patients who died were further characterised. Rheumatology diagnosis was categorised into four groups: (i) JIA, (ii) systemic lupus erythematosus (SLE), mixed-connective tissue disease (MCTD), vasculitis or other RMD (including Behcet’s disease, inflammatory myopathy, systemic sclerosis, localised scleroderma), (iii) auto-inflammatory syndromes (including tumour necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-associated auto-inflammatory syndromes (CAPS), and familial Mediterranean fever (FMF)), (iv) other (including chronic recurrent multifocal osteomyelitis, sarcoidosis, ocular inflammation, “other”, or was left blank).

Logistic regression (complete case) was used to assess factors associated with COVID-19 hospitalisation, including: age, sex, rheumatology diagnosis (four categories as above), obesity (BMI ≥30; tick box [EULAR] or combination of BMI and tick box [CARRA Registry and CARRA GPRD]), glucocorticoid use, and disease modifying anti-rheumatic drug (DMARD) use (none, conventional-synthetic DMARD only, biologic or targeted-synthetic DMARD only, combination therapy). Odds ratios (OR) and 95% confidence intervals (CI) are presented for each variable individually (univariable logistic regression). For the multivariable logistic regression, all variables in the univariable analysis were included as it was believed that each was an important factor to be accounted for. Disease activity was also included in the multivariable analysis with unknown (i.e. missing) included as an indicator variable (categories: remission, low, moderate to high, or unknown). Finally, dataset (EULAR or CARRA [CARRA Registry and CARRA GPRD]) was included in the multivariable model to account for differences between data collection. One patient with unknown sex was dropped from this analysis.
Two sensitivity analyses of the logistic regression were conducted. The first without inclusion of two patients retrospectively diagnosed with SLE after presentation with COVID-19 (both of whom died), given uncertainties regarding the possibility of COVID-19-induced autoimmune disease and the small number of deaths and serious illness reported in the data. The second excluded disease activity from the model due to the large amount of missing data.

Patients with JIA over 19 years old were included in a further descriptive analysis regarding age, sex, rheumatology diagnosis, hospitalisations and deaths.

**Results**

**CHILDREN AND YOUNG PEOPLE**
There were a total of 607 children and young people under the age of 19 years old included from 25 different countries; 464 from the EULAR COVID-19 Registry and 143 from the CARRA datasets (CARRA Registry and CARRA GPRD) (table 1). Of these, 499 (82%) were confirmed SARS-CoV-2 cases (majority with PCR; N=425), 399 (66%) were female, and median age was 14 years old (interquartile range [IQR] 9 to 16). The majority of children and young people had JIA (N=378; 62%); 140 with polyarticular (37% of JIA), 112 with oligoarticular (30% of JIA), 44 with enthesitis-related JIA (12% of JIA), 34 with systemic JIA (9% of JIA), 16 psoriatic (4% of JIA), and 33 other or unknown (9% of JIA). There were also 78 (13%) patients with auto-inflammatory syndromes, 47 (8%) with SLE or MCTD, 16 (3%) with vasculitis and 15 (2%) with inflammatory myopathy.

| Table 1: Patient characteristics, rheumatic disease information, and main COVID-19 outcomes of 607 children and young people under the age of 19 years with COVID-19. |
|---|
| All Patients | Not Hospitalised | Hospitalised |
| N | 607 | 564 (93%) | 43 (7%) |
| Dataset | | | |
| EULAR COVID-19 Registry | 464 (76%) | 437 (77%) | 27 (63%) |
| CARRA Datasets (CARRA Registry and CARRA COVID-19 GPRD) | 143 (24%) | 127 (23%) | 16 (37%) |
| Sex | | | |
| Female | 399 (66%) | 369 (65%) | 30 (70%) |
| Male | 207 (34%) | 194 (34%) | 13 (30%) |
| Unknown | 1 (<1%) | 1 (<1%) | 0 |
| Age, years | | | |
| Median (IQR) | 14 (9, 16) | 14 (10, 16) | 14 (8, 17) |
| Range | 1 to 18.9 | 1 to 18.9 | 2 to 18 |
| Primary rheumatology diagnoses | | | |
| Juvenile Idiopathic Arthritis (JIA) | 378 (62%) | 360 (64%) | 18 (42%) |
| Polyarticular | 139 (23%) | 137 (24%) | 2 (5%) |
| Oligoarticular | 112 (18%) | 108 (19%) | 4 (9%) |
| Systemic | 34 (6%) | 29 (5%) | 5 (12%) |
| Psoriatic | 16 (3%) | 16 (3%) | 0 |
| Enthesitis-related Other / Unknown | Systemic Lupus Erythematosus / MCTD / Vasculitis / Other RMD* | Auto-inflammatory syndromes (e.g. TRAPS, CAPS, FMF) | Other** |
|-----------------------------------|---------------------------------------------------------------|--------------------------------------------------|---------|
| 44 (7%)                           | 33 (5%)                                                      | 87 (14%)                                        | 64 (11%)|
| 39 (7%)                           | 31 (6%)                                                      | 73 (13%)                                        | 60 (11%)|
| 5 (12%)                           | 2 (5%)                                                       | 14 (33%)                                        | 4 (9%)  |

| Comorbidities | |
|---------------|---|
| None stated   | 505 (83%) |
| Ocular inflammation | 38 (6%) |
| Obesity (BMI ≥30) | 34 (6%) |
| Asthma        | 7 (1%)   |

| Disease activity |
|------------------|
| Remission        | 194 (32%) |
| Low              | 159 (26%) |
| Moderate         | 40 (7%)   |
| High             | 6 (1%)    |
| Unknown***       | 208 (34%) |

| Confirmed or Suspected |
|------------------------|
| Confirmed              | 499 (82%) |
| Suspected              | 108 (18%) |

| Most frequently reported symptoms |
|-----------------------------------|
| Asymptomatic                      | 140 (23%) |
| Fever                             | 236 (39%) |
| Cough                             | 181 (30%) |
| Rhinorrhea                        | 111 (18%) |
| Headache                          | 107 (18%) |
| Anosmia                           | 105 (17%) |

| Treatment at onset of COVID-19 infection |
|-----------------------------------------|
| Any DMARD                               | 423 (70%) |
| csDMARD monotherapy                     | 143 (24%) |
| b/tsDMARD monotherapy                   | 156 (26%) |
| Combination therapy (cs and bDMARD)     | 124 (20%) |
| Any csDMARD                             | 267 (44%) |
| Methotrexate                            | 198 (33%) |
| Antimalarials                           | 48 (8%)   |
| Mycophenolate                           | 28 (5%)   |
| Cyclophosphamide                        | 0         |
| Any b/tsDMARD                           | 280 (46%) |
| Anti-TNF inhibitor                      | 200 (33%) |
| IL-6 inhibitor                          | 30 (5%)   |
| IL-1 inhibitor                          | 19 (3%)   |
| Rituximab                               | 11 (2%)   |
| JAK inhibitor                           | 6 (1%)    |
| Glucocorticoids                         | 66 (11%)  |
| In combination with cs/btsDMARD         | 56 (9%)   |

| Required Hospitalisation |
|--------------------------|
| Yes                      | 43 (7%)  |
The majority of patients did not report any comorbidities (83%), although 38 (6%) had ocular inflammation (largely uveitis in association with JIA), and 34 (6%) were reported to be obese. Less than 1% reported comorbid inflammatory bowel disease, diabetes mellitus, or renal disease. Twelve (2%) patients reported more than one comorbidity.

Of these 607 children and young people, 43 (7%) were admitted to hospital. A higher proportion were reported as hospitalised in CARRA data versus the EULAR registry (11% vs 6%), as well as those with SLE/MCTD (16%) and systemic JIA (15%) compared with other JIA patients (4%). One hundred and forty (23%) patients had asymptomatic COVID-19. The most common symptoms overall were fever (N=236; 39% of all patients) and cough (N=181; 30% of all patients), with hospitalised patients reporting fever more frequently (77% vs 36%).

Most patients (N=423; 70%) were on DMARD therapy at the time of COVID-19. There were 267 (44%) patients on a conventional-synthetic DMARD (predominantly methotrexate, N=198), 143 of those as monotherapy and 124 in combination with biologic DMARDs. No patients were on combination therapies of conventional-synthetic DMARDs with targeted-synthetic DMARDs. There were 280 (46%) patients on biologic or targeted-synthetic DMARDs (predominantly anti-TNF therapy, N=200), 156 of those as monotherapy. There were a similar proportion of hospitalised and non-hospitalised patients discontinuing either their conventional-synthetic, or biologic or targeted-synthetic DMARD therapy at the time of COVID-19 diagnosis (approximately one third). Eleven percent (N=66) of patients were receiving glucocorticoid treatment at the time of COVID-19; of these, 36 patients reported dosage with median dose 6.5 mg/kg (IQR 3.8 to 12.3).

Among those for whom disease activity at the time of COVID-19 had been recorded, the majority were in remission (N=194; 49% of those with data) or had low disease activity (N=159; 40% of those with data). Disease activity at the time of COVID-19 was unavailable for 208 (34%) patients, primarily from the CARRA datasets and the EULAR French data subset (non-recorded at all in the French data subset). Hospitalised patients more often had moderate (9% vs 6%) or high (7% vs <1%) disease activity than non-hospitalised patients.
Three patients died with PCR confirmed SARS-CoV-2 (table 2). One death in a female <5 years old with a pre-existing auto-inflammatory syndrome (unknown disease activity status), on low dose glucocorticoids and methotrexate (described in further detail elsewhere[12]). Two deaths occurred in subjects from lower-resource areas who were diagnosed with SLE around the same time as they developed COVID-19 (one with SLE manifestations recognised at the time of COVID-19 presentation, another with preceding SLE manifestations but not yet diagnosed).

Table 2: Description of the three fatalities in children and young people with COVID-19.

| Patient | Age   | Sex | Rheumatology Diagnosis                | Comorbidities | Glucocorticoids | Rheumatology Treatment          | Disease Activity | Time from COVID onset to death |
|---------|-------|-----|----------------------------------------|---------------|-----------------|----------------------------------|-----------------|-------------------------------|
| 1       | <15 years | Female | Systemic Lupus Erythematosus | None | None | Antimalarials Intravenous Immunoglobulin | High | 8 days |
| 2       | <10 years | Female | Systemic Lupus Erythematosus | None | Yes (dose unknown) | None | High | 9 days |
| 3       | <5 years | Female | Auto-inflammatory syndrome | None | Yes (low dose) | Methotrexate | Unknown | 7 days |

Factors associated with hospitalisation in children and young people with COVID-19 (Table 3) included diagnosis of SLE/MCTD, vasculitis or other RMD (OR 4.3; 95% CI 1.7, 11) or auto-inflammatory syndromes (OR 3.0; 95% CI 1.1, 8.6) compared with JIA, and obesity (OR 4.0; 95% CI 1.3, 12). When the analysis was repeated, (i) excluding the two patients who died who were retrospectively diagnosed with SLE after presentation with COVID-19 (supplementary table 1), and (ii) excluding disease activity as a confounder (supplementary table 2), the estimates did not change substantially.

Table 3: Factors associated with hospitalisation in children and young people with COVID-19 (N=606).

|                          | Univariable Odds Ratio (95% Confidence Intervals) | Multivariable Odds Ratio* (95% Confidence Intervals) |
|--------------------------|---------------------------------------------------|-----------------------------------------------------|
| Female (vs Male)         | 1.2 (0.6, 3.8)                                    | 1.1 (0.6, 2.4)                                      |
| Age (years)              | 1.0 (0.9, 1.1)                                    | 1.0 (0.9, 1.0)                                      |
| Rheumatic Disease        |                                                   |                                                     |
|                          | JIA [comparator] 3.8 (1.8, 8.1)*                   | [comparator] 4.3 (1.7, 11)*                         |
|                          | SLE/MCTD, Vasculitis 2.0 (0.8, 4.9)               | 3.0 (1.1, 8.6)*                                    |
|                          | Auto-inflammatory syndromes 1.3 (0.4, 4.1)        | 1.7 (0.5, 5.5)                                      |
|                          | Other [comparator] 1.3 (0.4, 4.1)                  |                                                     |
| Obesity                  | 3.1 (1.2, 8.0)*                                   | 4.0 (1.3, 12)*                                     |
| Glucocorticoid use       | 2.7 (1.3, 5.9)*                                   | 2.1 (0.8, 5.6)                                     |
| DMARD use                |                                                   |                                                     |
|                          | None stated [comparator] 0.9 (0.4, 2.1)           | [comparator] 0.6 (0.2, 1.7)                         |
|                          | csDMARD only 0.9 (0.4, 2.1)                       | 1.5 (0.6, 3.6)                                     |
|                          | b/tsDMARD only 0.9 (0.4, 2.1)                     |                                                     |
|                          | Combination therapy 0.5 (0.2, 1.3)                 | 0.4 (0.1, 1.5)                                     |
**Biologic or targeted-synthetic (b/ts); conventional-synthetic (cs); disease modifying anti-rheumatic drug (DMARD); juvenile idiopathic arthritis (JIA); mixed-connective tissue disease (MCTD); systemic lupus erythematosus (SLE). #Adjusted for disease activity (remission, low, moderate to high, or unknown) and dataset (EULAR COVID-19 Registry or CARRA [CARRA Registry and CARRA COVID-19 GPRD]). *p<0.05**

**ADULTS**

There were 99 adults with JIA, 82 from the EULAR COVID-19 Registry and 17 from the CARRA dataset, with a median age of 26 years (IQR 20 to 34, range 19 to 72 years old). Of these adults, 76 (77%) were confirmed cases (majority with PCR; N=66), nine were hospitalised, and two died. The two deaths were in females with oligoarticular JIA with PCR confirmed SARS-CoV-2. One was 31-40 years old with moderate disease activity receiving glucocorticoid (dose 10mg) and combination conventional-synthetic DMARD with anti-TNF therapy at the time of COVID-19 diagnosis, with concomitant inflammatory bowel disease. The other was 61-70 years old in remission receiving no glucocorticoid or DMARD therapy, with asthma, diabetes, and hypertension.

**Discussion**

This is the most significant global investigation to date of short-term COVID-19 outcomes in children and young people with RMDs. Of the 607 cases reported, 7% were hospitalised, although less than one-in-five of these needed oxygen or ventilation, and three patients died. There were no associations between DMARD treatment (conventional-synthetic, biologic/targeted-synthetic, or combination therapy, compared with no DMARD treatment), or glucocorticoid use, with hospitalisation. However, children and young people with SLE/MCTD, vasculitis, other RMDs or auto-inflammatory syndromes were more likely to be hospitalised compared with those with JIA. As in multiple other reports in non-disease-specific populations, obesity represented a risk factor for more severe COVID-19 outcome.

These initial results are reassuring against the occurrence of severe COVID-19 illness (excluding multisystem inflammatory syndrome in children [MIS-C]) in the majority of individuals with paediatric RMDs, with only one-in-fifteen children and young people with RMDs with COVID-19 reporting hospitalisation. Using the same database structure, almost half of the cases reported in adults with RMDs were fatal cases, likely representing a significant bias in reporting.[5] If this same bias is present in the paediatric reports, it is possible that outcomes are even more favourable in this younger population, with many children and young people with RMDs experiencing milder COVID-19 not reporting the case to their physician, who in turn cannot report to the registries. The ad-hoc nature of voluntary reporting to these data sources prevents a population-based analysis.

Nonetheless, although uncommon in all children and young people, those with RMDs other than JIA (predominantly SLE/MCTD, vasculitis, or auto-inflammatory syndromes) were more likely to have serious outcomes, which is not surprising given the typically greater systemic involvement and need for more aggressive immunosuppressive therapy than the majority of individuals with JIA. In addition, patients with more severe JIA are often treated with anti-TNF DMARD therapies, which have been associated with less severe COVID-19 disease in some adult reports compared with other
therapies.[13–15] In adults with RMDs, those with SLE were at increased risk of COVID-19-related hospitalisation, and those with comorbidities such as hypertension, cardiovascular disease, chronic lung disease, chronic kidney disease, and diabetes, have been identified as being at increased risk of COVID-19-related hospitalisation and death.[5,13] Regarding obesity as a risk factor for more severe COVID-19, our data is in agreement with other studies evidencing poorer COVID-19 outcomes with obesity in the adult general population.[4,16] That obesity is also associated with severe COVID-19 in children is a new finding.

This analysis is the largest investigation of COVID-19 in children and young people with RMDs globally. However, it was not without limitations. SARS-CoV-2 infection reported to the combined registries included both presumptively diagnosed and confirmed cases, introducing possible misclassification bias. The authors believe this is not likely to have substantially confounded our results as the majority of severe COVID-19 cases would have been reported. In the treatment of COVID-19 deaths, we noted no significant difference in results of serious COVID-19 illness when excluding the two subjects without RMD diagnoses established prior to their presentation with COVID-19. Several limitations in data collection so far precluded drawing conclusions regarding other factors that have been shown to be associated with poor outcomes: (1) approximately one-third of the combined dataset had missing RMD disease activity, preventing meaningful exploration of this factor on short-term outcomes; (2) substantial differences in reporting of race and ethnicity between data sources prevented cross-mapping between efforts and we were unable to analyse whether Black, Asian and minority ethnic (BAME) groups with paediatric RMDs are at higher risk of COVID-19-related death compared with those of white ethnicity, as has been reported for the general population[4,17] and (3) we did not have access to data on SARS-CoV-2 variant types although all the data were collected prior to the emergence of the Omicron variant.[18] Our registries did not capture vaccination status at the time of data collection (although most cases occurred prior to approval of vaccination for the relevant age groups) and we do not capture long-term or late outcomes such as “long COVID”[19,20] or MIS-C. Finally, our data sources received very limited reporting from low-resource healthcare areas internationally.

In conclusion, understanding the impact of COVID-19 infection on children and young people with RMDs is important to inform national protection, education (such as school attendance), and vaccination guidance. We report the most significant investigation to date of short-term outcomes of COVID-19 in over 600 children and young people with RMDs. The majority of children and young people with RMDs appear to do well and experience mild COVID-19 disease. However, where hospitalisations did occur, they were more likely among those with SLE/MCTD, vasculitis, auto-inflammatory syndromes, and other paediatric RMDs compared with their peers with JIA. The data also showed for the first time that obesity is a relevant comorbidity also in children with RMDs, supporting that protection measures in those children should be strictly followed. While mortality has been reported, it appears to occur rarely in high-resource healthcare areas.
Acknowledgments

We wish to thank all rheumatology providers who entered data into the EULAR COVID-19 Registry, and the CARRA databases. We also wish to acknowledge the efforts provided by Anne Dennos and Dr. Timothy Beukelman for reviewing the CARRA Registry COVID-19 ESI reports.

This work could not have been accomplished without the aid of the following organizations: The NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the Arthritis Foundation and members of the Paediatric Rheumatology European Society (PReS). We would also like to thank all participants and hospital sites that recruited patients for the CARRA Registry. The authors thank the CARRA Registry and CARRA-sponsored COVID-19 Global Paediatric Database site principal investigators, sub-investigators and research coordinators (see supplementary materials).

In Germany, the cases were collected via an add-on module of the national paediatric rheumatologic database (NPRD), which is currently funded by the German Research Foundation (Kick-COVID, MI 2760/1-1) and the companies Chugai, GSK and Novartis. We are grateful to all patients and their parents for participating in the NPRD and to all colleagues who contributed to this data collection (see supplementary materials).

Data availability statement

Data are available upon reasonable request. Applications to access the data should be made to the EULAR COVID-19 Registry and CARRA Data and Sample Sharing Committees.

Competing Interests statement

RC reports personal AstraZeneca shares, unrelated to this manuscript. IKP reports personal fees by Novartis, SOBI, Chugai, Pfizer, AbbVie, BMS, all unrelated to this manuscript. FOR reports consulting/speaker’s fees from Abbvie, Novartis, Pfizer and Sobi, all unrelated to this manuscript. NMW reports personal consultant fees from UCB, BMS, all unrelated to this manuscript. AS reports personal fees from lectures for AbbVie, Celltrion, MSD, Janssen, Lilly, Roche, BMS, and Pfizer, all unrelated to this manuscript. EM reports personal consultant fees from Boehringer Ingelheim Portugal, Lda, all unrelated to this manuscript. LPCDR received support for specific activities: grants from Abbvie, Novartis, Lilly Portugal, Amgen Biofarmacêutica, Grünenthal S.A., MSD, Medac, A. Menarini Portugal - Farmacêutica, S.A., Pfizer, UCB Pharma, Roche Farmacêutica Química, Lda; and non-financial support from Pfizer, and Grünenthal GmbH, all unrelated to this manuscript. PMM has received consulting/speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript, and is supported by the National Institute for Health Research (NIHR), University College London Hospitals (UCLH), Biomedical Research Centre (BRC). MN reports funding from Childhood Arthritis & Rheumatology Research Alliance, Inc (CARRA) to his informatics research and operations group at Boston Children’s Hospital in its capacity as the CARRA Data Warehouse and associated work for CARRA and the CARRA Registry and has sponsored the COVID-19 Global Pediatric Rheumatology Database study, of which he is the Principal Investigator. MN also serves as Director of Informatics for CARRA, for which he receives no direct compensation but do receive research sponsorship for CARRA-related research, development, and operations (see above). He is also a co-investigator of the CARRA Registry and site Principal Investigator at Massachusetts General Hospital. KLH reports non-personal speaker’s fees from Abbvie and grant income from BMS, UCB, and Pfizer, all unrelated to this manuscript, and is supported by the NIHR Manchester Biomedical Research Centre.
All other authors report no disclosures.

**Ethics statements**
Patient consent for publication not required.

**Patient and Public Involvement statement**
PPIE not included in this manuscript.

**Disclaimer**
The views expressed here are those of the authors and do not necessarily represent the views of the European Alliance of Associations for Rheumatology (EULAR), the (UK) National Health Service (NHS), the National Institute for Health Research (NIHR), the (UK) Department of Health, the (US) National Institutes of Health, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), or any other organisation.

**Funding**
This publication was supported by funding from the European Alliance of Associations for Rheumatology (EULAR), and NIH/NCATS Colorado CTSA Grant Number UL1 TR002535, and CARRA. PPM is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre. KLH is supported by the NIHR Manchester Biomedical Research Centre.

**Presented at**
This manuscript was presented in part at the 2021 Annual European Congress of Rheumatology (virtual) June 2-5th, and the 2021 Paediatric Rheumatology European Society (PReS) e-congress and PReS (virtual) young investigators meeting September 18-20th.
References

1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet].
2. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch. Dis. Child. 2021.
3. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 Infection among Children and Adolescents Compared with Adults: A Systematic Review and Meta-Analysis. JAMA Pediatr. 2021.
4. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;
5. Strangfeld A, Schäfer M, Gianfrancesco MAMA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;
6. Kroon FPB, Najm A, Alunno A, et al. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis. 2021;annrheumdis-2021-221575.
7. Bhopal SS, Bagaria J, Olabi B, et al. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc. Heal. 2021.
8. Harwood R, Yan H, Camara NT Da, et al. Which children and young people are at higher risk of severe disease and death after SARS-CoV-2 infection: a systematic review and individual patient meta-analysis. medRxiv. 2021;
9. The COVID-19 Global Rheumatology Alliance. The COVID-19 Global Rheumatology Alliance [Internet].
10. EULAR. EULAR COVID-19 Registry [Internet].
11. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;
12. Schmidt A, Peters S, Knaus A, et al. TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. npj Genomic Med. 2021;
13. Gianfrancesco M, Hyrich KL, Hyrich KL, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;
14. Izadi Z, Brenner EJ, Mahil SK, et al. Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open. 2021;
15. Regierer AC, Hasseli R, Schäfer M, et al. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open. 2021;
16. Docherty AB, Harrison EM, Green CA, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv. 2020;
17. Gianfrancesco MA, Leykina LA, Izadi Z, et al. Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021;
18. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern [Internet]. 2021.

19. Simpson FK, Lokugamage AU. The elephant and the blind men: The children of long covid. BMJ. 2021.

20. Bhopal SS, Absoud M. Vaccinating children to prevent long covid? More caution is needed in interpreting current epidemiological data. BMJ. 2021.
Supplementary Materials

Supplementary Table 1: Factors associated with hospitalisation in children and young people with COVID-19, excluding the two patients who died with SLE (N=604).

|                                | Univariable Odds Ratio (95% Confidence Intervals) | Multivariable Odds Ratio* (95% Confidence Intervals) |
|--------------------------------|--------------------------------------------------|-----------------------------------------------------|
| **Female (vs Males)**          | 1.1 (0.6, 2.2)                                   | 1.1 (0.5, 2.3)                                      |
| **Age (years)**                | 1.0 (0.9, 1.1)                                   | 1.0 (0.9, 1.0)                                      |
| **Rheumatic Disease**          |                                                  |                                                     |
| JIA                            | [comparator]                                     | [comparator]                                        |
| SLE/MCTD, Vasculitis           | 3.3 (1.5, 7.1)*                                  | 3.7 (1.4, 9.7)*                                     |
| Auto-inflammatory syndromes    | 2.0 (0.8, 4.9)                                   | 2.9 (1.0, 8.2)*                                     |
| Other                          | 1.3 (0.4, 4.1)                                   | 1.6 (0.5, 5.3)                                      |
| **Obesity**                    | 3.3 (1.3, 8.4)*                                  | 4.1 (1.4, 12)*                                      |
| **Glucocorticoid use**         | 2.5 (1.2, 5.6)*                                  | 2.3 (0.8, 6.2)                                      |
| **DMARD use**                  |                                                  |                                                     |
| None stated                    | [comparator]                                     | [comparator]                                        |
| csDMARD only                   | 0.9 (0.4, 2.1)                                   | 0.6 (0.2, 1.7)                                      |
| b/tsDMARD only                 | 1.0 (0.5, 2.3)                                   | 1.4 (0.6, 3.6)                                      |
| Combination therapy            | 0.5 (0.2, 1.4)                                   | 0.5 (0.1, 1.5)                                      |

Biologic or targeted-synthetic (b/ts); conventional-synthetic (cs); disease modifying anti-rheumatic drug (DMARD); juvenile idiopathic arthritis (JIA); mixed-connective tissue disease (MCTD); systemic lupus erythematosus (SLE). #Adjusted for disease activity (remission, low, moderate to high, or unknown) and dataset (EULAR COVID-19 Registry or CARRA [CARRA Registry and CARRA COVID-19 GPRD]). *p<0.05
Supplementary Table 2: Factors associated with hospitalisation in children and young people with COVID-19, excluding disease activity (N=606).

|                         | Univariable Odds Ratio (95% Confidence Intervals) | Multivariable Odds Ratio* (95% Confidence Intervals) |
|-------------------------|--------------------------------------------------|-----------------------------------------------------|
| Female (vs Males)       | 1.2 (0.6, 3.8)                                   | 1.2 (0.6, 2.4)                                      |
| Age (years)             | 1.0 (0.9, 1.1)                                   | 1.0 (0.9, 1.0)                                      |
| Rheumatic Disease       |                                                  |                                                     |
| JIA                     | [comparator]                                     | [comparator]                                        |
| SLE/MCTD, Vasculitis    | 3.8 (1.8, 8.1)*                                  | 3.6 (1.4, 8.9)*                                    |
| Auto-inflammatory syndromes | 2.0 (0.8, 4.9)                               | 2.0 (0.7, 5.5)                                      |
| Other                   | 1.3 (0.4, 4.1)                                   | 1.6 (0.5, 5.2)                                      |
| Obesity                 | 3.1 (1.2, 8.0)*                                  | 3.1 (1.1, 9.0)*                                    |
| Glucocorticoid use      | 2.7 (1.3, 5.9)*                                  | 2.1 (0.9, 5.2)                                      |
| DMARD use               |                                                  |                                                     |
| None stated             | [comparator]                                     | [comparator]                                        |
| csDMARD only            | 0.9 (0.4, 2.1)                                   | 0.6 (0.2, 1.7)                                      |
| b/tsDMARD only          | 0.9 (0.4, 2.1)                                   | 1.3 (0.5, 3.2)                                      |
| Combination therapy     | 0.5 (0.2, 1.3)                                   | 0.5 (0.1, 1.6)                                      |

Biologic or targeted-synthetic (b/ts); conventional-synthetic (cs); disease modifying anti-rheumatic drug (DMARD); juvenile idiopathic arthritis (JIA); mixed-connective tissue disease (MCTD); systemic lupus erythematosus (SLE). #Adjusted for dataset (EULAR COVID-19 Registry or CARRA [CARRA Registry and CARRA COVID-19 GPRD]). *p<0.05
The authors thank the following CARRA Registry site principal investigators, sub-investigators and research coordinators:

N. Abel, K. Abulaban, A. Adams, M. Adams, R. Agbayani, J. Aiello, S. Akoghlanian, C. Alejandro, E. Allenspach, R. Alperin, M. Alpizar, G. Amarilyo, W. Ambler, E. Anderson, S. Ardoin, S. Armendariz, E. Baker, I. Balboni, S. Balevic, L. Ballenger, S. Ballinger, N. Balmuri, F. Barba Barbr-Smiley, L. Barillas-Arias, M. Basiaga, K. Baskins, M. Becker, H. Bell-Brunson, E. Beltz, H. Benham, S. Banseler, W. Bernal, T. Beukelman, T. Bigley, B. Binstadt, C. Black, M. Blakley, J. Bohnsack, J. Boland, A. Boneparch, S. Bowman, C. Bracaglia, E. Brooks, M. Brown, H. Brunner, M. Buckley, M. Buckley, H. Bukulmez, D. Bullock, B. Cameron, S. Canna, L. Cannon, P. Carper, V. Cartwright, E. Cassidy, L. Cerracchio, E. Chalom, J. Chang, A. Chang-Hofman, V. Chauhan, P. Chira, T. Chinn, K. Chundru, H. Clairman, D. Co, A. Confair, H. Conlon, R. Connor, A. Cooper, J. Cooper, S. Cooper, C. Correll, R. Corvalan, D. Costanzo, R. Cron, L. Curiel-Duran, T. Curington, M. Curry, A. Dalrymple, A. Davis, C. Davis, T. Davis, F. De Benedetti, D. De Ranieri, J. Dean, F. Dedegolu, M. De Guzman, N. Delnay, V. Dempsey, E. De Santis, T. Dickson, J. Dingel, B. Donaldson, E. Dorsey, S. Dover, J. Dowling, J. Drew, K. Dric, Q. Du, K. Duarte, D. Durkee, E. Duverger, D. Duygesen, A. Eberhard, M. Eckert, K. Ede, B. Edelheit, C. Edens, C. Edens, Y. Edgerly, M. Elder, B. Ervin, S. Fadrhonc, C. Page, D. Fair, M. Falcon, L. Favier, S. Federici, B. Feldman, J. Fennell, I. Ferguson, P. Ferguson, B. Ferreira, R. Ferruccio, K. Fields, T. Finkel, M. Fitzgerald, C. Fleming, O. Flynn, L. Fogel, E. Fox, M. Fox, L. Franco, M. Freeman, K. Fritz, S. Froese, R. Fuhlbrigg, J. Fuller, N. George, K. Gerhold, D. Gerstbacher, M. Gilbert, M. Gillispey-Taylor, E. Giverc, C. Godiwalla, I. Goh, H. Goheer, D. Goldsmith, E. Gotschlich, A. Gotte, B. Gottlieb, C. Gracia, T. Graham, S. Grevich, T. Griffin, J. Griswold, A. Grom, M. Guevara, P. Guittar, M. Guzman, M. Hager, T. Hahn, O. Halyabar, E. Hammelev, M. Hance, A. Hanson, L. Harel, S. Haro, J. Harris, O. Harry, E. Hartigan, J. Hausmann, A. Hay, K. Hayward, J. Heiart, K. Hekil, L. Henderson, M. Henrickson, A. Hersh, K. Hickey, P. Hill, S. Hillyer, L. Hiraki, M. Hiskey, P. Hobday, C. Hoffart, M. Holland, M. Hollander, S. Hong, M. Horwitz, J. Hsu, A. Huber, J. Huggins, J. Hui-Yuen, C. Hung, J. Huntington, A. Huttenlocher, M. Ibarra, L. Imundo, C. Inman, A. Insalaco, A. Jackson, S. Jackson, K. James, G. Janow, J. Jaquith, S. Jared, N. Johnson, J. Jones, J. Jones, K. Jones, S. Jones, S. Joshi, L. Jung, C. Justice, A. Justinianno, N. Karan, K. Kaufman, A. Kemp, E. Kessler, U. Khalsa, B. Kienzle, S. Kim, Y. Kimura, D. Kingsbury, M. Kitcharoensakkul, T. Klausmeier, K. Klein, M. Klein-Gitelman, B. Kompelien, A. Kosikowski, L. Kovalick, J. Kracker, S. Kramer, C. Kremer, J. Lai, J. Lam, B. Lang, S. Lapidus, B. Lapin, A. Lasky, D. Latham, E. Lawson, R. Laxer, P. Lee, P. Lee, T. Lee, L. Lentini, M. Lerman, D. Levy, S. Li, S. Lieberman, L. Lim, C. Lin, N. Ling, M. Lingis, M. Lo, D. Lovell, D. Lowman, N. Luca, S. Luovich, C. Madison, J. Madison, S. Magni Manzoni, B. Malla, J. Maller, M. Malloy, M. Mannion, C. Manos, L. Marques, A. Martyniuk, T. Mason, S. Mathus, L. McAllister, K. McCarthy, K. McConnell, E. McCormick, D. McCurdy, P. McCurdy Stokes, S. McGuire, I. McHale, A. McMonagle, C. McMullen-Jackson, E. Meidan, E. Mellins, E. Mendoza, R. Mercado, A. Merritt, L. Michalski, P. Miettunen, M. Miller, D. Milojevic, E. Mirizio, E. Misajon, M. Mitchell, R. Modica, S. Mohan, K. Moore, L. Moorothy, S. Morgan, E. Morgan Dewitt, C. Moss, T. Moussa, V. Mruk, A. Murphy, E. Muscal, R. Nadler, B. Nahal, K. Nanda, N. Nasah, L. Nassi, S. Nativ, M. Natter, J. Neely, B. Nelson, L. Newhall, L. Ng, J. Nicholas, R. Nicolai, P. Nigrovic, J. Nocton, B. Nolan, E. Oberle, B. Obispo, B. O'Brien, O. Okeke, M. Oliver, J. Olson, K. O'Neil, K. Onel, A. Orandi, M. Orlando, S. Osei-Onomah, R. Oz, E. Pagano, A. Paller, N. Pan, S. Panupattanapong, M. Pardeo, J. Paredes, A. Parsons, J. Patel, K. Pentakota, P. Pepmueller, T. Pfeiffer, K. Phillipi, D. Pires Maranon, K. Phillipi, L. Ponder, R. Pooni, S. Pralahad, S. Pratt, S. Protopapas, B. Puplava, J. Quach, M. Quinlan-Waters, C. Rabinovich, S. Radhakrishna, J. Rafko, J. Raisian, A. Rakeworth, C. Ramirez, E. Ramsay, S. Ramsey, R. Randell, A. Reed, A. Reed, A. Reed, H. Reid, K. Remmel, A. Repp, A. Reyes, A. Richmond, M. Riebschleger, S. Ringold, M. Riordan, M. Riskalla, M. Ritter, R. Rivas-Chacon, A. Robinson, E. Rodela, M. Rodriguez, K. Rojas, T. Ronis, M. Rosenkranz, B.
Rosolowski, H. Rothermel, D. Rothman, E. Roth-Wojcicki, K. Rouster – Stevens, T. Rubinstein, N. Ruth, N. Saad, S. Sabbagh, E. Sacco, R. Sadun, C. Sandborg, A. Sanni, L. Santiago, A. Sarkissian, S. Savani, L. Scalzi, L. Schanberg, S. Scharnhorst, E. Schleifman, H. Schmeling, K. Schmidt, E. Schmitt, R. Schneider, K. Schollaert-Fitch, G. Schulte, T. Seay, C. Seper, J. Shalen, R. Sheets, A. Shelly, S. Shenoi, K. Shergill, J. Shirley, M. Shichov, C. Shivers, E. Silverman, N. Singer, V. Sivaraman, J. Sletten, A. Smith, C. Smith, J. Smith, J. Smith, E. Smitherman, J. Soep, M. Son, S. Spence, L. Spiegel, J. Spitznagle, R. Sran, H. Srinivasalu, H. Stapp, K. Steigerwald, Y. Sterba Rakovchik, S. Stern, A. Stevens, B. Stevens, R. Stevenson, K. Stewart, C. Stingl, J. Stokes, M. Stoll, E. Stringer, S. Sule, J. Sumner, R. Sundel, M. Sutter, R. Syed, G. Syverson, A. Szymbonski, S. Taber, R. Tal, A. Tambralli, A. Taneja, T. Tanner, S. Tapani, G. Tarshish, S. Tarvin, L. Tate, A. Taxter, J. Taylor, M. Terry, M. Teshar, A. Thatayatikom, B. Thomas, K. Tiffany, T. Ting, A. Tipp, D. Toib, K. Torok, C. Toruner, H. Toth, S. Tse, V. Tubwell, M. Twilt, S. Uriguen, T. Valcarcel, H. Van Mater, L. Vannoy, C. Varghese, N. Vasquez, K. Vazzana, R. Vehe, K. Veiga, J. Velez, J. Verbsky, G. Vilar, N. Volpe, E. von Scheven, S. Vora, J. Wagner, L. Wagner-Weiner, D. Wahezi, H. Waite, J. Walker, H. Walters, T. Wampler Muskardin, L. Waqr, M. Waterfield, M. Watson, A. Watts, P. Weiser, J. Weiss, P. Weiss, E. Wershba, A. White, C. Williams, A. Wise, J. Woo, L. Woolnough, T. Wright, E. Wu, A. Yalcindag, M. Yee, E. Yen, R. Yeung, K. Yomogida, Q. Yu, R. Zapata, A. Zartoshti, A. Zeft, R. Zeft, Y. Zhang, Y. Zhao, A. Zhu, C. Zic.

The authors also thank for the following COVID-19 GPRD Investigators: Muna Almutairi (Adan Hospital), Susan Canny (Seattle Children's Hospital), Ingram Chang (Hospital for Special Surgery), Margaret Chang (Boston Children's Hospital), Ezra Cohen (Boston Children's Hospital), Rachael Connor (Childrens National Meical Center), Cassandra Davis (University of Utah Hospitals and Clinics), Mar Christopher Epetia (University of the Philippines - Philippine General Hospital), Cari Gallagher (Indiana University School of Medicine), Ruby Haviv (Meir medical center), Raju Khubchandani (SRCC Children's Hospital), Karen Joy Kimseng (Chong hua hospital), Samara Mendieta (Hospital Materno Infantil ISSEMyM), Katharine Moore (The Children's Hospital Colorado), Theresa Wampler Muskardin (New York University Langone Medical Center), Kabita Nanda (Seattle Children's Hospital), Peter Nigrovic (Boston Children's Hospital), Aarit Patel (University of Virginia), Clare Peckenpaugh (University of Utah Hospitals and Clinics), Jean-Philippe Proulx-Gauthier(CHUL - Département de pédiatrie, Université Laval), Sarah Ringold (Seattle Children's Hospital), Jaya Sonkar (University of Texas Medical Branch), Alfonso Ragnar Torres-Jimenez (Instituto Mexicano Del Seguro Social. Hospital General Centro Medico Nacional La Raza. Pediatric Rheumatology), Dawn Wahezi (Children's Hospital at Montefiore), Stephen Wong (Seattle Children's Hospital).

In Germany, the cases were collected via an add-on module of the national pediatric rheumatologic database (NPRD), which is currently funded by the German Research Foundation (Kick-COVID, MI 2760/1-1) and the companies Chugai, GSK and Novartis. We are grateful to all patients and their parents for participating in the NRPD and to all colleagues who contributed to this data collection: Prof. Dr. Kirsten Minden, Berlin, Martina Niewerth, MPH, Berlin, Dr. Claudia Sengler, Berlin; Prof. Dr. Jasmin Kümmerle-Deschner Tübingen; Dr. Ariane Klein, Sankt Augustin; Prof. Dr. Johannes-Peter Haas, Garmisch-Partenkirchen; Prof. Dr. Hermann Girschick, Berlin; Dr. Regina Hühn, Halle; Prof. Dr. Michael Borte, Leipzig; Dr. Anton Hospach, Stuttgart; Prof. Dr. Markus Hufnagel, Freiburg; PD Dr. Jürgen Brunner, Innsbruck; Dr. Frank Dressler, Hannover; Dr. Ralf Trauzeddel, Berlin; Prof. Dr. Andrea Skrabl-Baumgartner, Graz; Dr. Gregor Dückers, Krefeld; Dr. Annett Lamprecht, Magdeburg; Tanja Hinze, Münster; Dr. Peggy Rühmer, Plauen; PD Dr. Daniel Windschall, Sendenhorst. Data were also submitted from the German Society of Pediatric Infectiology (DGPI) registry, for which we sincerely thank Dr. Jakob Armann, Dresden.